Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2022/07/043691
CTRI/2022/07/043691
Recruiting
未知

Fluoro-deoxy-glucose positron emission tomography computed tomography (FDG PET-CT) in the staging of patients of high-risk urothelial and renal malignancies

AIIMS Jodhpur0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
AIIMS Jodhpur
Status
Recruiting
Last Updated
3 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\. All patients attending the urology OPD of AIIMS, Jodhpur and more than 18 years of age with imaging or biopsy findings suggestive of primary renal malignancy TNM stage T2 and/ or N1 and above.
  • •2\. All patients attending the urology OPD of AIIMS, Jodhpur and more than 18 years of age with imaging or biopsy findings suggestive of muscle invasive carcinoma urinary bladder or N1 and above.
  • •3\. All patients giving written, informed patient.
  • •4\. All patients willing and able to comply with the required procedures of the study in the opinion of the investigator.

Exclusion Criteria

  • •1\. Any patient not giving consent for the study.
  • •2\. Any patient with poor performance status or life expectancy excluding him/ her from curative surgery or radiotherapy or use of oral/ intravenous therapy.
  • •3\. Known case of renal, UTUC bladder malignancy post curative intent.
  • •4\. Known case of metastatic malignancy already on treatment for advanced disease.
  • •5\. Patient with compromised renal function in whom administration of IV iodinated contrast is contraindicated.
  • •6\. Patient with known hypersensitivity to the radiotracer or contrast agent to be used.
  • •7\. A history of other known malignancy within the last two years with the exception of melanoma or any other known skin cancer.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Fluorodeoxyglucose-positron emission tomography for avoidance of futile direct laryngoscopies under general anaesthesia with taking of biopsies in patients with suspicion on recurrent laryngeal carcinoma after radiotherapyaryngeal carcinomaCancerLaryngeal cancer
ISRCTN89530459Vrije University Medical Centre (VUMC) (The Netherlands)150
Recruiting
Not Applicable
[18F]-Fluorodeoxyglucose Positron Emission Tomography for In Vivo Assessment of Glucose Metabolism in Pheochromoctyoma and Paragangliomaadrenal tumours1002911210014710
NL-OMON38518niversitair Medisch Centrum Sint Radboud25
Completed
Not Applicable
[18F]-Fluorodeoxyglucose Positron Emission Tomography in Lung Tumour Assessment, Research into Characteristicslung cancernon-small cell lung carcinoma1003866610029107
NL-OMON32809niversitair Medisch Centrum Sint Radboud54
Active, not recruiting
Not Applicable
Combined 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) and Metomidate Imaging for Adrenal Neoplasia (FAMIAN-Study) - a Diagnostic Studyindeterminate adrenal neoplasiasTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
EUCTR2012-003604-13-DEniversity Hospital Wuerzburg220
Active, not recruiting
Not Applicable
18F-Fluorothymidine Positron Emission Tomography as an early predictor of response to neoadjuvant therapy in patients with locally advanced breast carcinoma - NDBreast carcinoma classified as cT1b,c, T2, T3, or cT4 a-c, cN0-2, N3, M0MedDRA version: 9.1Level: HLTClassification code 10006289
EUCTR2010-020472-34-ITISTITUTO EUROPEO DI ONCOLOGIA